Background and Objectives: Studies have shown a lower prevalence of anti-SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD), including amongst those receiving biological therapy. Aims were to determine the seroprevalence of anti-SARS-CoV-2 antibodies in IBD patients and to assess any association between seropositivity and IBD characteristics. Materials and Methods: Serum from adult IBD patients was prospectively collected between December 2020 and January 2021 and analyzed for anti-SARS-CoV-2 antibodies. Information about IBD characteristics and SARS-CoV-2 exposure risk factors was collected and analyzed. Serum from non-IBD healthcare workers formed the control group. Results: 311 IBD patients on biologics and 75 on mesalazine were enrolled. Ulcerative colitis (UC) extension ( p < 0.001), Crohn’s disease (CD) phenotype ( p = 0.009) and use of concomitant corticosteroids ( p < 0.001) were significantly different between the two IBD groups. Overall seroprevalence among IBD patients was 10.4%. The control group showed a prevalence of 13.0%, not significantly different to that of IBD patients ( p = 0.145). Only a close contact with SARS-CoV-2 positive individuals and the use of non-FFP2 masks were independently associated with a higher likelihood of seropositivity amongst IBD patients. Conclusion: In IBD patients, the prevalence of anti-SARS-CoV-2 antibodies is not determined by their ongoing treatment. Disease-related characteristics are not associated with a greater risk of antibody seropositivity.
【저자키워드】 COVID-19, Seroprevalence, Inflammatory bowel disease, anti-SARS-CoV-2 antibodies, 【초록키워드】 Corticosteroid, Treatment, SARS-CoV-2, Corticosteroids, therapy, antibody, Seroprevalence, risk, risk factor, anti-SARS-CoV-2, healthcare worker, Mask, Inflammatory bowel disease, Prevalence, serum, anti-SARS-CoV-2 antibodies, Characteristics, anti-SARS-CoV-2 antibody, Patient, Seropositivity, phenotype, patients, IBD, ulcerative colitis, association, close contact, Crohn’s disease, determined by, contact with, control group, Colitis, material, extension, aims, likelihood, SARS-CoV-2 positive individuals, mesalazine, greater, enrolled, shown, analyzed, collected, significantly, receiving, was collected, determine, groups, not significantly different, SARS-CoV-2 positive individual, 【제목키워드】 Italy, Wave, second,